The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders

Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneopla...

Descripción completa

Detalles Bibliográficos
Autores principales: Maddison, Paul, Titulaer, Maarten J., Verschuuren, Jan J., Gozzard, Paul, Lang, Bethan, Irani, Sarosh R., Sabater, Lidia, Graus, Francesc, Murray, Andrea, Chapman, Caroline J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier/North-Holland 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375907/
https://www.ncbi.nlm.nih.gov/pubmed/30445363
http://dx.doi.org/10.1016/j.jneuroim.2018.11.003
Descripción
Sumario:Antibodies to SOXB1 proteins in patients with paraneoplastic disorders are associated with small-cell lung cancer (SCLC), particularly in Lambert-Eaton myasthenic syndrome (LEMS). We aimed to establish if SOX2 antibodies could be used to identify SCLC and other tumours found in a range of paraneoplastic disorders and controls. SOX2 antibodies were detectable in 61% of patients with LEMS-SCLC, and in other paraneoplastic disorders, such as opsoclonus-myoclonus and paraneoplastic cerebellar degeneration, only when there was an underlying SCLC. SOX2 antibodies are specific (>90%) markers for SCLC, but are rarely found in patients with other tumours, whether neurological symptoms are present or not.

Ejemplares similares